Monoclonal antibodies against β-amyloid currently in phase III clinical... | Download Scientific Diagram
Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer's disease: a systematic review - ScienceDirect
Biogen and Eisai try to defend Alzheimer's drug BAN2401 against skeptics | Fierce Biotech
LATEST FINDINGS ON LECANEMAB - CLINICAL EFFICACY, ARIA RATES, BIOMARKERS RELATIONSHIP TO CLINICAL OUTCOMES AND DOSING REGIMENS - PRESENTED AT AD/PD™ 2022 ANNUAL MEETING
Biogen: BAN2401 Not A Home Run Anymore, But Still Holds Some Promise — The Non-Consensus
Chad Swanson, PhD, on the Promising Effect of BAN2401 on Alzheimer Disease Progression
Alzheon Pipeline | Preserving Future Memories
Alzheimer's disease drug development pipeline: 2017 - Cummings - 2017 - Alzheimer's & Dementia: Translational Research & Clinical Interventions - Wiley Online Library
P4‐704: BAN2401 SHOWS STRONGER BINDING TO SOLUBLE AGGREGATED AMYLOID‐BETA SPECIES THAN ADUCANUMAB - Lannfelt - 2019 - Alzheimer's & Dementia - Wiley Online Library
The amyloid cascade and Alzheimer's disease therapeutics: theory versus observation | Laboratory Investigation
IJMS | Free Full-Text | Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease | HTML
S-1/A
Eisai Signs a Research Collaboration with BioArctic to Characterize BAN2401's Mechanism of Action
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody | Alzheimer's Research & Therapy | Full Text
Novel Treatments for Alzheimer Disease Disorders - Practical Neurology
Alzheimer's disease: Recent treatment strategies - ScienceDirect
Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval | Semantic Scholar
S-1
View of Immunotherapy Targeting Amyloid-β Peptides in Alzheimer's Disease | Exon Publications
The Development of Pharmacological Therapies for Alzheimer's Disease | SpringerLink
IJMS | Free Full-Text | Revisiting the Amyloid Cascade Hypothesis: From Anti-Aβ Therapeutics to Auspicious New Ways for Alzheimer's Disease | HTML
Anti-Amyloid-β Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise - Biological Psychiatry
Lecanemab Reduces Blood Biomarkers of Alzheimer Disease - Practical Neurology
A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease | Nature Reviews Neurology
BioArctic's new collaboration with Eisai on BAN2401
Amyloid-beta immunotherapy: the hope for Alzheimer disease?
Frontiers | Antibody Engineering for Optimized Immunotherapy in Alzheimer's Disease | Neuroscience
Biogen Results: Time To Change The Paradigm In Alzheimer's Disease (NASDAQ:BIIB) | Seeking Alpha
